Healthpoint Biotherapeutics announces HP802-247 clinical trial results
04:00 EDT 7 Aug 2012 | Pharmaceutical Business Review
Biopharmaceutical company Healthpoint Biotherapeutics has announced the results for its Phase 2b clinical trial investigating the efficacy of HP802-247 in venous leg ulcers, which is published in journal The Lancet .
Original Article: Healthpoint Biotherapeutics announces HP802-247 clinical trial results
More From BioPortfolio on "Healthpoint Biotherapeutics announces HP802-247 clinical trial results"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
